We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum‐based chemoradiotherapy treatment.
- Authors
Duran, Goretti; Aguín, Santiago; Cruz, Raquel; Barros, Francisco; Giráldez, José María; Bernárdez, Beatriz; López‐López, Rafael; Carracedo, Ángel; Lamas, María Jesús
- Abstract
Background: Platinum‐based chemoradiotherapy (CRT) is the standard treatment for locally advanced head and neck squamous‐cell carcinomas (HNSCC), and most patients experience serious toxicities. The aim of this study was to investigate the association between candidate genes involved in radiation/platinum pathways and acute toxicity of CRT to determine the predictive value of these polymorphisms for toxicity. Methods: Thirty‐six selected single nucleotide polymorphisms (SNPs) in 29 genes were genotyped in 110 patients treated with cisplatin‐based CRT. DNA was obtained from blood samples, and SNP analysis was performed using a MassARRAY iPLEX Gold (Sequenom) method. Results: Patients with ERCC1 rs11615‐C allele (P = .0066), ERCC1 rs735482‐C allele (P = .0204), and ERCC4 rs1799801‐C allele (P = .0286) had lower risk of grade 2‐3 hematologic toxicity. In addition, the presence of G allele of GSTP1 was associated with a significantly lower risk of severe dysphagia (P = .0004). Conclusion: Polymorphisms in ERCC1 and GSTP1 may act as prognostic factors of acute toxicity during treatment with CRT in HNSCC patients.
- Subjects
HEAD &; neck cancer; THERAPEUTICS; SINGLE nucleotide polymorphisms; SQUAMOUS cell carcinoma
- Publication
Head & Neck, 2019, Vol 41, Issue 8, p2704
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.25754